No insider has reported a holding in the last two years, so insiders are counted in "Everyone else".
None.
None.
No insider has filed a notice of proposed sale (Form 144) for Syros Pharmaceuticals, Inc. in the last 12 months.
No 13F manager reports holding Syros Pharmaceuticals, Inc..
| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
DE
Master Investment Portfolio
|
$0.09 | 870 | 0.00% | 0.00% | June 30, 2026 |
|
GA
Guggenheim Active Allocation Fund
Guggenheim Active Allocation Fund
|
$0.01 | 34 | 0.00% | 0.00% | August 31, 2026 |
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
SB
Samsara BioCapital, L.P.
5%+ holder
13D · 2.6%
|
707.1K | 2.64% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
|
SB
Samsara BioCapital GP, LLC
5%+ holder
13D · 2.6%
|
707.1K | 2.64% | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
|
||||||
1 more holders behind a free account
See every insider and 5%+ holder of Syros Pharmaceuticals, Inc..
Sign up freeLoading...